Regen Biopharma INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OID
Regen Biopharma reported a net profit of $991,927 for Q2 2026, a significant turnaround from a net loss of $19,354 in the prior year, largely driven by derivative income.
OID
Regen Biopharma reported a significant increase in net loss and a critically low cash balance, raising substantial doubt about its ability to continue as a going concern.
OID
Regen Biopharma, Inc. reported a significant increase in net loss for the nine months ended June 30, 2025, and disclosed substantial doubt about its ability to continue as a going concern.
OID
Regen Biopharma, an early-stage biopharmaceutical company, reported a significantly increased net loss and critically low cash balance for the six months ended March 31, 2025, leading to substantial doubt about its ability to continue as a going concern.
OID
Regen Biopharma's Q1 2025 results show an increased net loss primarily due to derivative losses, despite a reduction in operating expenses.
OID
10-Q: Regen BioPharma Reports Q3 2024 Results, Cites Ongoing Losses and Need for Additional Financing
Regen BioPharma's Q3 2024 report reveals continued operating losses and a reliance on equity financing, highlighting the company's ongoing need for capital.
OID
Regen Biopharma's Q2 2024 report reveals continued operating losses and a reliance on equity financing to sustain operations.
OID
Regen BioPharma's Q1 2024 report shows a net loss of $349,760 and highlights the company's ongoing need for additional financing.